Breaking News

Tweet TWEET

Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference

Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor
Conference

BERKELEY HEIGHTS, N.J., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Cyclacel
Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the
"Company"), a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
serious disorders, today announced that the Company will present at the 16th
Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel
in New York City, New York. Spiro Rombotis, President and Chief Executive
Officer, will provide an overview of the Company and its progress in key
programs on Monday, February 10, 2014 at 11:00 a.m. Eastern in the Duke of
Windsor room.

Cyclacel's presentation will be webcast live and archived for 90 days on the
Corporate Presentations page of the Cyclacel website at www.cyclacel.com.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is
the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the
FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly,
and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic
leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic
cancer and in particular those carrying gBRCA mutations. Cyclacel's strategy
is to build a diversified biopharmaceutical business focused in hematology and
oncology based on a development pipeline of novel drug candidates. Please
visit www.cyclacel.com for additional information.

© Copyright 2014 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The
Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. 

CONTACT: Company:
         Paul McBarron
         (908) 517-7330
         pmcbarron@cyclacel.com
        
         Investor Relations:
         Russo Partners LLC, Robert Flamm
         (212) 845-4226
         robert.flamm@russopartnersllc.com

Cyclacel Pharmaceuticals logo
 
Press spacebar to pause and continue. Press esc to stop.